375 Photos and videos
Full video now available for SOFIE's recent FAP In Focus event.
Eli Lilly: FAP targeted therapeutics could transform oncology and there is a lot of money in this field.
vimeo.com/1198897285?share=c…
#AVCT
2
4
19
524
#AVCT advisors P Schoffski and R Jones report no significant PFS benefit and no safety advantage of Brightline-1 over Dox in STS.
Doxorubicin is hard to beat in STS - just need to tackle the side effects.
#AVCT
aacrjournals.org/clincancerr…
3
4
62
7,783
Interesting new paper on ADCs and brain metastases co-authored by #AVCT advisor S Modi
pre|CISION® Eliminates the Severe Cardiac Toxicity of Doxorubicin
CC Jan '26: "Every [solid tumour] cancer, from brain cancer... to pancreatic... we can address it"
pmc.ncbi.nlm.nih.gov/article…
3
8
66
2,247
Effective delivery of the A in ADCs limited by TME.
FAP CAFs reduce antibody delivery in HNSCC and PDAC.
Efficacy in solid tumours needs tissue penetration, CAFs may contribute to therapeutic resistance by limiting drug delivery
#AVCT antibody-free and exploits FAP TME.
1
4
59
5,482
FDA doesn't require completed Phase 1 for Breakthrough Designation - early efficacy signals in heavily pretreated P1 patients, 74% DCR and high unmet need were sufficient for exatecan-based sofetabart mipitecan.
#AVCT
Breakthrough Therapy granted this week for P1 ADC w/ proprietary linker tech exatecan payload
Manageable safety, no MTD
Heavily pretreated patients, early efficacy
"Limited treatment options, poor outcomes for patients"
Precedent for #AVCT AVA6103?
targetedonc.com/view/fda-gra…
1
7
82
10,336
#AVCT newly listed as a "partnering company" of BIO International this month.
Sounds high profile.
convention.bio.org/participa…
6
7
93
3,830
Another new paper from Roche - next-gen FAP-targeted combo therapies for difficult tumours like pancreatic, with activation only in the TME to avoid systemic immune/drug activation.
#AVCT may be of interest Roche 😁
jitc.bmj.com/content/14/5/e0…
New paper published this week by Roche - interesting to see they have a very current interest in FAP-targeted immunotherapy and the TME
aacrjournals.org/clincancerr…
#AVCT
1
1
59
5,227
"Not enough patients have experienced disease progression for us to be able to calculate median PFS."
#AVCT
In this video presentation, Avacta CEO Christina Coughlin reviews the new faridoxorubicin program data. avacta.wistia.com/s/2hfpqeap… #AVCT
3
9
83
6,143
"A striking reminder: despite advances in linker technology, a substantial proportion of ADC payload exposure still occurs through systemic circulation, raising ongoing questions about the balance between targeted delivery and off-target toxicity.”
#AVCT
Jun 2
#ASCO26 ADC Insights from Dr. Paolo Tarantino - Laura Venegas
@PTarantinoMD
oncodaily.com/voices/laura-v…
1
36
3,104
3
8
87
10,291
#AVCT newswire press release picked up by Firstword Pharma just now
firstwordpharma.com/story/75…
2
4
51
4,298
$650m upfront, possible $10bn total.
Eight early-stage Innovent assets and four Pfizer-proposed discovery programmes, including antibody-drug conjugates (ADCs) with unique payloads.
Nothing yet at clinical stage.
There's money around.
#AVCT
firstwordpharma.com/story/74…
1
2
59
8,990
#AVCT just wrapping up at UK Biotech Day, and even got a little spot on the 'step and repeat' board (never knew they had a name)
linkedin.com/posts/uk-biotec…
More #AVCT publicity - "Tackling undruggable targets - Innovation approaches and success stories"
ukbiotechday.org/agenda.html
linkedin.com/posts/ukbiotech…
#AVCT
4
7
66
7,420
Eli Lilly presenting on FAP Targeting In (oncology) Therapy at a SOFIE conference on Sunday - potentially an update or mention of the FiREBOLT trial using #AVCT's pre|CISION tech
sofie.com/event/2026-annual-…
5
4
60
5,246